Navigation Links
China Sky One Medical, Inc. Signs Distribution Agreement with Harbin Baolong Pharmaceutical Company
Date:7/15/2008

HARBIN, China, July 15 /Xinhua-PRNewswire-FirstCall/ -- China Sky One Medical, Inc. ("China Sky One Medical" or "the Company") (Amex: CSY), a leading fully integrated pharmaceutical company producing external use, over- the-counter drugs in the People's Republic of China ("PRC"), announced today that it signed an agreement with Harbin Baolong Pharmaceutical Company on July 12 to distribute the Company's prescription drugs.

China Sky One, which has a history of producing external use and over-the- counter drugs, has recently acquired pharmaceutical companies that develop and produce prescription drugs. As a result, prescription drugs manufactured by China Sky One have doubled and now make up approximately 30% of its total product lines. Harbin Baolong Pharmaceutical Company, which has an extensive distribution network for prescription drugs in China, achieved revenues of in excess of RMB 500 million (USD $73.1 million) in each of the last two years.

The agreement, which initially runs over five years, has a total estimated value of approximately RMB 61.5 million (USD $ 9 million.) To date, China Sky One has been selling five of its prescription drugs through Baolong's distribution network, which it expects will generate sales of approximately RMB 20.5 million (USD $3 million) from August 2008 to December 2008.

"We are excited to be cooperating with Harbin Baolong Pharmaceutical Company," said Mr. Yan-Qing Liu, Chairman, CEO and President of China Sky One Medical, Inc. "We are confident that our move into the prescription drug market via Baolong's strong distribution channel represents a solid opportunity for future growth and can ultimately help us expand our market share and increase profitability going forward."

About China Sky One Medical, Inc.

China Sky One Medical, Inc., a Nevada corporation, is a holding company. The Company engages in the manufacturing, marketing and distribution of pharmaceutical, medicinal and diagnostic products. Through its wholly-owned subsidiaries, Harbin Tian Di Ren Medical Science and Technology Company ("TDR") and Harbin First Bio- Engineering Company Limited ("First"), the Company manufactures and distributes over-the-counter pharmaceutical products, which make up its major revenue source. For more information, visit http://www.skyonemedical.com .

Safe Harbor Statement

Certain of the statements made in the press release constitute forward- looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by the use of forward- looking terminology such as "believe," "expect," "may," "will," "should," "project," "plan," "seek," "intend," or "anticipate" or the negative thereof or comparable terminology. Such statements typically involve risks and uncertainties and may include financial projections or information regarding our future plans, objectives or performance. Actual results could differ materially from the expectations reflected in such forward-looking statements as a result of a variety of factors, including the risks associated with the effect of changing economic conditions in The People's Republic of China, variations in cash flow, reliance on collaborative retail partners and on new product development, variations in new product development, risks associated with rapid technological change, and the potential of introduced or undetected flaws and defects in products, and other risk factors detailed in reports filed with the Securities and Exchange Commission from time to time.

For more information, please contact:

Company Contact:

China Sky One Medical, Inc.

Ms. Yanwei Zhang, Board Secretary

Tel: +86-451-5399-4064

Email: cntiandiren@yahoo.com.cn

Investor Relations Contact:

CCG Investor Relations

Mr. Crocker Coulson, President

Tel: +1-646-213-1915

Email: crocker.coulson@ccgir.com

Mr. Richard Micchelli, Financial Writer

Tel: +1-646-454-4516

Email: richard.micchelli@ccgir.com

Web: http://www.ccgir.com


'/>"/>
SOURCE China Sky One Medical, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. AmeriCares Purchases 2nd BLU-MED Deployable Field Hospital for China Earthquake Relief
2. Closing coal-burning power plant in China and improved cognitive development in children
3. China Kangtai Cactus Biotech Inc. Launches Cactus Cattle Feed and Cactus Fish Feed
4. AmeriCares Meets Long-Term Health Needs of Disaster Victims in China and Myanmar
5. Chindexs United Family Healthcare Launches ChinaHealthWatch.org - A global resource for travelers to China
6. China Medicine Releases White Paper on Developing Recombinant Aflatoxin-Detoxifizyme
7. Chindex International, Inc. Announces Receipt of Key Regulatory ApprovalsChina SFDA Certificates Received Include Intuitive Surgical daVinci S
8. China Improves Safety Management on Imported Foods in Preparation for Olympic Games
9. AMDL Signs Letter of Intent to Purchase China-Based Pharmaceutical Distribution Company
10. Cynosure Expands Presence in China with the Opening of Sales Office in Beijing
11. Golden Meditech Pioneers into Chinas Hospital Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... ... March 28, 2017 , ... “A Prophets Bones”: a thrilling adventure that reveals the mystery of ... were things that his parents and teachers had asked of him that he had neglected ... going to defy the Almighty Creator. There were some who would have felt themselves to ...
(Date:3/27/2017)... ... 27, 2017 , ... New patients who have sleep apnea in ... or without a referral. Sleep apnea is often left untreated because patients are not ... and chronic snoring. , Dr. Braasch seeks to raise awareness of sleep apnea ...
(Date:3/27/2017)... ... 27, 2017 , ... Drs. Bruce Trimble and Michelle Parker ... a referral. Trimble Dental offers a variety of services to meet each patient’s ... patients have discolored, crooked or missing teeth in Eau Claire, WI, Drs. Trimble ...
(Date:3/27/2017)... White Plains, NY (PRWEB) , ... March 27, 2017 , ... ... honoring Root Canal Awareness Week by teaching their patients about the key role this ... canal therapy from an experienced endodontist. To better serve those who need a ...
(Date:3/27/2017)... ... 2017 , ... This is the second major release since ... 2014. It is the culmination of collaborative efforts by members of the OSEHRA ... Member Zato Health co-funded the ONC certification and provided key technical support throughout ...
Breaking Medicine News(10 mins):
(Date:3/27/2017)... LEXINGTON, Mass. , March 27, 2017   Pulmatrix, ... innovative inhaled therapies to address serious pulmonary diseases, today announced ... allergic fungal disease, cystic fibrosis and asthma to its ... Richard B. Moss , MD, ... former Director of the Cystic Fibrosis Center at Stanford University, ...
(Date:3/27/2017)... March 27, 2017 The global ... USD 16.0 billion by 2025, according to a new ... of chronic diseases is anticipated to be responsible for ... thereby widens the scope for growth during the forecast ... population, which is highly susceptible to chronic diseases, is ...
(Date:3/27/2017)... and BOSTON , ... a leading global pharmaceutical company and Paratek Pharmaceuticals, ... the development and commercialization of innovative therapies based ... 3 trials of sarecycline for the treatment of ... primary efficacy endpoints. Sarecycline is a once-daily, oral, ...
Breaking Medicine Technology: